Antiphospholipid antibodies and placental development

Fetal and Maternal Medicine Review

Volumn 9, Issue 4, 1997, Pages 181-197

  Rote, Neal S ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; HUMAN; PLACENTA DEVELOPMENT; PLACENTA DISORDER; PREGNANCY; REVIEW; TROPHOBLAST;

EID: 0031433293     PISSN: 09655395     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0965539597000120     Document Type: Review

References (119)

1. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Brit Med J Clin Res Ed 1983; 287: 1088-89.
2. Lechner K. Lupus anticoagulants and thrombosis. In: M. Verstraete, J. Vermylen, R. Lijnen, J. Arnout eds, Thrombosis and Haemostasis. Leuven, Belgium: Leuven University Press, 1987: 525-47.
3. Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259: 550-54.
4. Branch DW, Scott JR. Clinical implications of anti-phospholipid antibodies: the Utah experience. In: E.N. Harris, T. Exner, G.R.V. Hughes, R.A. Asherson eds. Phospholipid-Binding Antibodies. Boca Raton: CRC Press, 1991: 335-46.
5. 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Human Reprod 1995; 10: 2001-2005.
6. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87: 489-93.
7. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Amer J Obstet Gynecol 1989; 161: 369-73.
8. Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Brit J Obstet Gynaecol 1993; 100: 909-13.
9. Kochenour NK, Branch DW, Rote NS, Scott JR. A new postpartum syndrome associated with antiphospholipid antibodies. Obstet Gynecol 1987; 69: 460-468.
10. Francois A, Freund M, Daffos F, Remy P, Aiach M, Jacquot C. Repeated fetal losses and the lupus anticoagulant. Ann Intern Med 1988; 109: 993-94.
11. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989; 73:541-45.
12. Sher G, Feinman M, Zouves C, Kuttner G, Maassarani G, Salem R et al. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Human Reprod 1994; 9: 2278-83.
13. Kutteh WH, Yetman DL, Chantilis SJ, Grain J. Effect of antiphospholipid antibodies in women undergoing in-vitro fertilization: role of heparin and aspirin. Human Reprod 1997; 12: 1171-75.
14. Asherson RA, Khamashta MA, Gil A, Vazquez J-J, Chan O, Baguley E et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Amer J Med 1989; 86: 391-99.
15. Elias M, Eldor A. Thromboembolism in patients with the 'lupus'-type circulating anticoagulant. Arch Intern Med 1984; 144: 510-15.
16. Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patient with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-59.
17. Brey RL, Coull BM. Antiphospholipid antibodies: origin, specificity and mechanisms of action. Stroke 1992; 23 [suppl I]: 15-18.
18. Kent MN, Vogt E, Fyffe R, Alvarez F, Ng AK, Rote NS. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J Rheum 1997; 24: 1725-33.
19. Shapiro SS, Thiagarajan P. Lupus Anticoagulants. Prog Hemostasis Thromb 1982; 6: 263-85.
20. Triplett DA, Brandt JT. Lupus anticoagulants: Misnomer, paradox, riddle, epiphenomenon. Hematol Pathol 1988; 2: 121-23.
21. Triplett DA. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 1989; 20: 52-67.
22. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost 1991 65: 320-22.
23. Triplett DA. Antiphospholipid antibodies, lupus anticoagulants and thromboembolic disease. Haematologica 1995 80: 122-26.
24. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-45.
25. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anti-cardiolipin test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987 68: 215-22.
26. Obringer AR, Rote NS, Walter A. Antiphospholipid antibody binding to bilayer-coated glass microspheres. J Immun Methods 1995; 185: 81-93.
27. Harris EN. Special report. The Second International Anticardiolipin Standardization Workshop/The Kingston Antiphospholipid Antibody Study (KAPS) Group. Am J Clin Pathol 1990; 94: 476-84.
28. Coulam CB, McIntyre JA, Wagenknecht D, Rote N. Interlaboratory inconsistencies in detection of anticardiolipin antibodies. Lancet 1990; 335: 865.
29. Peaceman AM, Silver RK, MacGregor SN, Socol ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 1992; 166: 1780-87.
30. Harris EN, Gharavi AE, Loizou S, Derue G, Chan JK, Patel BM et al. Crossreactivity of antiphospholipid antibodies. J Clin Lab Immun 1985; 16: 1-6.
31. Branch DW, Rote NS, Scott JR. The demonstration of the lupus anticoagulant by an enzyme-linked immunosorbant assay (ELISA). Clin Immun Immunopath 1986; 39: 296-307.
32. Branch DW, Rote NS, Dostal D, Scott JR. Association of lupus anticoagulant with antibody against phosphatidylserine. Clin Immun Immunopath 1987; 42: 63-75.
33. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1-6.
34. Rote NS, Dostal-Johnson D, Branch DW. Antiphospholipid antibodies and recurrent pregnancy loss: Correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. Am J Obstet Gynecol 1990; 163: 575-84.
35. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fert Steril 1996; 66: 540-46.
36. Rauch J, Janoff AS. Role of monoclonal antibodies in understanding the interactions between anti-phospholipid antibodies and phospholipids. In: Harris N, Exner T, Hughes GRV, Asherson RA eds. Phospholipid-Binding Antibodies. Boca Raton, CRC Press 1991; 108-22.
37. Galli M, Barbui T, Zwaal RFA, Comfurius P, Bevers EM. Editorial: Antiphospholipid antibodies: involvement of protein cofactors. Haematologica 1993; 78: 1-4.
38. Galli M, Comfurius P, Maassen C, Hemker HC, DeBaets MH, van Breda-Vriesman PJC et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 2: 1544-57.
39. 2-Glycoprotein I (apolipoprotein H). Proc Natl Acad Sci 1990; 87: 4120-24.
40. Chamley LW, McKay EJ, Pattison NS. Cofactor dependent and cofactor independent anticardiolipin antibodies. Thromb Res 1991; 61: 291-99.
41. Roubey RA. The antiphospholipid antibody syndrome: new pieces to the puzzle. Bull Rheum Dis 1994; 43: 6-8.
42. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
43. 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. J Rheum 1997; 24: 1545-51.
44. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-78.
45. Daum G. Lipids of mitochondria. Biochim Biophys Acta 1985; 822: 1-42.
46. Op den Kamp JAF. Lipid asymmetry in membranes. Ann Rev Biochem 1979; 48: 47-71.
47. Nakashima S, Suganuma A, Matsui A, Nozawa Y. Thrombin induces a biphasic 1,2-diacyl glycerol production in human platelets. Biochem J 1991; 275: 355-61.
48. McEvoy L, Williamson P, Schlegel RA. Membrane phospholipid asymmetry as a determinant of erythrocyte recognition by macrophages. Proc Natl Acad Sci, USA 1986; 83: 3311-15.
49. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immun 1992; 148: 2207-16.
50. Sessions A, Horowitz AF. Differentiation related differences in the plasma membrane phospholipid asymmetry of myogenic and fibrogenic cells. Biochim Biophys Acta 1983; 728: 103-11.
51. Bevers EM, Comfurius EP, Van Rijn J, Hemker C, Zwaal RFA. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-36.
52. Zwaal RFA, Bevers EM, Comfurius P, Rosing J, Tilly RH, Verhallen PF. Loss of membrane phospholipid asymmetry during activation of blood platelets and sickled red cells; mechanisms and physiological significance. Mol Cell Biochem 1989; 91: 23-31.
53. Rote NS, Ng AK, Dostal-Johnson DA, Nicholson SL, Siekman R. Immunologic detection of phosphatidylserine externalization during thrombin-induced platelet activation. Clin Immun Immunopath 1993; 66: 193-200.
54. Adler RR, Ng AK, Rote NS. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Biol Reprod 1995; 53: 905-10.
55. Rote NS, Chang J, Katsuragawa H, Ng AK, Lyden TW, Mori T. Expression of phosphatidylserine-dependent antigens on the surface of differentiating BeWo human choriocarcinoma cells. Amer J Reprod Immun 1995; 33: 114-21.
56. Vogt E, Ng AK, Rote NS. Anti-phosphatidylserine antibody removes annexin V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. Amer J Obstet Gynecol 1997; 177: 964-72.
57. Sune A, Bette-Bobillo P, Bienvenue A, Fellmann P, Devaux PF. Selective outside-inside translocation of amino-phospholipids in human platelets. Biochem 1987; 26: 2972-78.
58. Zwaal RFA. Scrambling membrane phospholipids and local control of blood clotting. NIPS 3: 57-61.
59. Le DT, Rapaport SI, Rao VM. Studies of the mechanism for enhanced cell surface factor VIIa/ tissue factor activation of factor X on fibroblast monolayers after their exposure to N-ethylmaleimide. Thromb Haemo 1994; 72: 848-55.
60. Zachowski A, Henry J-P, Devaux PF. Control of transmembrane lipid asymmetry in chromaffin granules by and ATP-dependent protein. Nature 1989; 340: 75-76.
61. Zwaal RFA, Bevers EM, Comfurius P. Static and dynamic lipid asymmetry in cell membranes. In: Proceedings of the International STAGO Symposium on "Phospholipid-binding Antibodies and Thrombosis", Paris, 14 May 1993, 2-3.
62. Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez AE et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47: 849-54.
63. Out HJ, Kooijman CD, Bruinse HW, Derksen RHWM. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41: 179-86.
64. Rauch J, Meng Q-H, Tannenbaum H. Lupus anticoagulant and anti-platelet properties of human hybridoma autoantibodies. J Immunol 1987; 139: 2598-604.
65. Shi W, Chong BH, Chesterman CN. Beta2glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulant. Blood 1993; 81: 1255-62.
66. Lin Y-L, Wang C-T. Activation of human platelets by rabbit anticardiolipin antibodies. Blood 1992; 80: 3135-43.
67. Weiner HM, Vardinon N, Yust I. Platelet antibody binding and spontaneous aggregation in 21 lupus anticoagulant patients. Vox Sang 1991; 61: 111-21.
68. Arvieux J, Roussel B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to α2-glycoprotein I. Thromb Haemost 1993; 2: 336-41.
69. Vismara A, Meroni PL, Tincani A, Harris EN, Barcellini W, Brucato A et al. Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 1988; 74: 247-53.
70. Cervera R, Khamashta MA, Font J, Ramirez G, D'Cruz D, Montalban J et al. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity 1991; 11: 1-6.
71. McCrae KR, de Michele A, Samuels P, Roth D, Kuo A, Meng Q-H et al. Detection of endothelial cell reactive immunoglobulin in patients with antiphospholipid antibodies. Br J Haematol 1991; 79: 595-605.
72. Del Papa N, Meroni PL, Tincani A, Harris EN, Pierangeli SS, Barcellini W et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheum 1992; 10: 37-42.
73. Walker TS, Triplett DA, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thrombosis Research 1988; 51: 267-81.
74. Le Roux G, Wautier M-P, Guillevin L, Wautier J-L. IgG binding to endothelial cells in systemic lupus erythematosus. Thromb Haemost 1986; 56: 144-46.
75. Lin L, Shroyer L, Walter A, Lyden TW, Ng AK, Rote NS. Monoclonal IgM antiphosphatidylserine antibody reacts against cytoskeleton-like structures in cultured human umbilical cord endothelial cells. Am J Reprod Immunol 1995; 33: 97-107.
76. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978; 30: 293-31.
77. Carreras LO, Vermylen JG. "Lupus" anticoagulant and thrombosis-possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48: 38-40.
78. Marchesi D, Parbtani A, Frampton G, Livio M, Remuzzi G, Cameron JS. Thrombotic tendency in systemic lupus erythematosus. Lancet 1981; 1: 719.
79. Ros JO, Tarres MV, Baucells MV, Maired JJ, Solano JT. Prednisone and maternal lupus anticoagulant. Lancet 1983; 2: 576.
80. Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Eng J Med 1986; 314: 1193-94.
81. Cosgriff TM, Martin BA. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis Rheum 1981; 24: 94-96.
82. Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor production by endothelial cells. J Immunol 1986; 137: 1532-37.
83. DeWolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142: 829-34.
84. Lochshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313: 152-56.
85. Althabe O, Labarrere C, Telenta M. Maternal vascular lesions in placentae of small-for-gestational-age infants. Placenta 1985; 6: 265-76.
86. Sheppard BL, Bonnar J. An ultrastructural study of utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. Br J Obstet Gynecol 88: 695-705.
87. Abramowsky CR, Vegas ME, Swinehart G, Gyves MT. Decidual vasculopathy of the placenta in lupus erythematosus. N Engl J Med 1980; 303: 668-72.
88. Kliman HJ, Feinman MA, Strauss JF III. Differentiation of human cytotrophoblasts into syncytiotrophoblasts in culture. Troph Res 1987; 2: 407-21.
89. Hamilton WJ, Boyd JD. Trophoblast in human utero-placental arteries. Nature 212: 906-908.
90. Williamson P, Schlegel RA. Back and forth: the regulation and function of transbilayer phospholipid movement in eukaryotic cells. Mol Membrane Biol 1994; 11: 199-216.
91. Obringer AR, Dean KW, Channel S, Rote NS. Membrane phospholipid translocase activity in JEG-3, a choriocarcinoma model of cytotrophoblast differentiation. Placenta 1997; 18: 421-26.
92. Lyden TW, Ng AK, Rote NS. Modulation of phosphatidylserine epitope expression on BeWo cells during forskolin treatment. Placenta 1993; 14: 177-86.
93. Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod 1997; 56: 50-58.
94. Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 1989; 264: 7944-49.
95. Romisch J, Schorlemmer U, Fickenscher K, Paques EP, Heimburger N. Anticoagulant properties of placenta protein 4 (Annexin V). Thromb Res 1990; 60: 355-66.
96. Rote NS, Lyden TW, Vogt E, Adler RR, Chang J, Katsuragawa H et al. Expression of phosphatidylserine epitopes during trophoblast membrane fusion: an alternative hypothesis for antiphospholipid antibody associated pregnancy disorders. In: F Dondero F, Johnson PM eds, Reproductive Immunology. New York: Serono Symposia Publications, Raven Press 1993; 97: 281-84.
97. Lyden TW, Vogt E, Ng AK, Johnson PM, Rote NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol 1992; 22: 1-14.
98. Katsuragawa H, Rote NS, Inoue T, Narukawa S, Kanzaki H, Mori T. Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts. Am J Obstet Gyn 1995; 177: 1592-97.
99. Hasegawa I, Takakuwa K, Adachi S, Kanazawa K. Cytotoxic antibody against trophoblast and lymphocytes present in pregnancy with intrauterine fetal growth retardation and its relation to anti-phospholipid antibody. J Reprod Immun 1990; 17: 127-39.
100. Blank M, Tincani A, Shoenfeld Y. Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheum 1994; 21: 100-104.
101. Vogt E, Ng AK, Rote NS. A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice. Am J Obstet Gynecol 1996; 174: 700-707.
102. Rote NS, Lyden TW, Vogt E, Ng AK. Antiphospholipid antibodies and placental development. In: Hunt JS ed, Immunobiology of Reproduction, New York: Springer-Verlag, 1994: 285-302.
103. Iwashita M, Watanabe M, Setoyama T, Mimuro T, Nakayama S, Adachi T et al. Effects of diacylglycerol and gonadotropin-releasing hormone on human chorionic gonadotropin release by cultured trophoblast cells. Placenta 1992; 13: 213-21.
104. Gleicher N, Harlow L, Zilberstein M. Regulatory effect of antiphospholipid antibodies on signal transduction: A possible model for autoantibody-induced reproductive failure. Am J Obstet Gynecol 1992; 167: 637-42.
105. DiSimone N, DeCarolis S, Lanzone A, Rosisvalle E, Giannice R, Caruso A. In vitro effect of antiphospholipid antibody-containing sera on basal and gonadotropin releasing hormone-dependent human chorionic gonadotropin release by cultured trophoblast cells. Placenta 1995; 16: 75-83.
106. Orr JW, Newton AC. Interaction of protein kinase C with phosphatidylserine. 1. Cooperativity in lipid binding. Biochem 1992; 31: 4661-67.
107. Orr JW, Newton AC. Interaction of protein kinase C with phosphatidylserine. 2. Specificity and regulation. Biochem 1992; 31: 4667-73.
108. Reza F, Igarashi K, Tokita S, Asai K, Aoki J, Asaoka Y et al. Anti-idiotypic monoclonal antibody recognizes a consensus recognition site for phosphatidylserine in phosphatidylserine-specific monoclonal antibody and protein kinase C. FEBS Lett 1994; 339: 229-33.
109. Raynal P, Hullin F, Ragab-Thomas JM, Fauvel J, Chap H. Annexin 5 as a potential regulator of annexin 1 phosphorylation by protein kinase C. In vitro inhibition compared with quantitative data on annexin distribution in human endothelial cells. Biochem J 1995; 292: 759-65.
110. Librach CL, Werb Z, Fitzgerald ML, Chiu K, Corwin NM, Esteves RA et al. 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. J Cell Biol 1991; 113: 437-49.
111. Librach CL, Feigenbaum SL, Bass KE, Cui T-Y, Verastas N, Sadovsky Y et al. Interleukin 1β regulates human cytotrophoblast metalloproteinase activity and invasion in vitro. J Biol Chem 1994; 269: 17125-31.
112. Graham CH, Lala PK. Mechanisms of placental invasion of the uterus and their control. Biochem Cell Biol 1992; 70: 867-74.
113. Burrows TD, King A, Loke YW. Expression of integrins by human trophoblast and differentiatial adhesion to laminin or fibronectin. Human Reprod 1993; 8: 475-84.
114. Damsky CH, Librach C, Lim K-H, Fitzgerald ML, McMaster MT, Janatpour M et al. Integrin switching regulates normal trophoblast invasion. Development 1994; 120: 3657-66.
115. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993; 91: 950-60.
116. Krikun G, Lockwood CJ, Wu X-X, Zhou X-D, Guller S, Calandri C et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 1994; 15: 601-12.
117. Rand JH, Wu X-X, Guller S, Gil J, Guha A, Scher J et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Amer J Obstet Gynecol 1994; 171: 1566-72.
118. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Eng J Med 1997; 337: 154-60.
119. Andree HA, Stuart MC, Hermens WT, Reutelingsperger CP, Hemker HC, Frederik PM et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267: 17907-12.